Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma - PubMed (original) (raw)

Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of treatment-naïve patients with pancreatic ductal adenocarcinoma.

Permuth JB, Park MA, Chen DT, Basinski T, Powers BD, Gwede CK, Dezsi KB, Gomez M, Vyas SL, Biachi T, Cortizas EM, Crowder S, Genilo-Delgado M, Green BL, Greene A, Gregg C, Hoffe SE, Jiang K, Kim B, Vasudevan V, Garcialopez De Llano J, Menon AA, Mo Q, MorenoUrazan LM, Mok S, Parker N, Rajasekhara S, Rasool G, Sinnamon A, Sparks L, Stewart PA, Tardif K, Tassielli AF, Teer JK, Tran DV, Turner KL, Vadaparampil ST, Whelan CJ, Douglas WG, Velanovich V, Karachristos A, Legaspi A, Meredith K, Molina-Vega MA, Huguet KL, Arnoletti JP, Bloomston M, Trevino J, Merchant NB, Pimiento JM, Hodul PJ, Malafa M, Fleming J, Judge SM, Jeong DK, Judge A. Permuth JB, et al. Front Oncol. 2024 Jul 23;14:1362244. doi: 10.3389/fonc.2024.1362244. eCollection 2024. Front Oncol. 2024. PMID: 39109281 Free PMC article.